12.11.2012 Views

COMBI 40+ ABI Auditory Brainstem Implant - Med-El

COMBI 40+ ABI Auditory Brainstem Implant - Med-El

COMBI 40+ ABI Auditory Brainstem Implant - Med-El

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />

<strong>Auditory</strong> <strong>Brainstem</strong> <strong>Implant</strong>


2<br />

<strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />

<strong>Auditory</strong> <strong>Brainstem</strong> <strong>Implant</strong><br />

The <strong>COMBI</strong> <strong>40+</strong> <strong>Auditory</strong> <strong>Brainstem</strong><br />

<strong>Implant</strong> (<strong>ABI</strong>) is a highly advanced<br />

technological system for individuals<br />

with hearing loss due to a<br />

nonfunctional auditory nerve, such as<br />

in cases of Neurofibromatosis Type 2<br />

(NF2). Bypassing the inner ear and<br />

auditory nerve, the <strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />

allows high-rate stimulation of the<br />

cochlear nucleus (CN) and can<br />

provide recipients a variety<br />

of sound sensations.<br />

N e u ro f i b ro m a t o s i s<br />

Type 2 (NF2)<br />

Neurofibromatosis Type 2 (NF2), also known<br />

as Bilateral Acoustic NF (BAN), is a rare<br />

genetic disorder that affects approximately 1<br />

in 40,000 individuals. NF2 can either be<br />

inherited or occur spontaneously without any<br />

apparent familial history. The gene defect was<br />

isolated in 1993 to the merlin tumor<br />

suppressor area of chromosome 22. NF2 is<br />

characterized by non-malignant tumor growth,<br />

primarily in the brain and spinal cord. A<br />

hallmark of NF2 is the presence of bilateral<br />

acoustic neuromas, which originate in the<br />

vestibular nerve and often invade the adjacent<br />

auditory nerve, causing progressive hearing<br />

loss and ultimately deafness. <strong>Auditory</strong><br />

<strong>Brainstem</strong> <strong>Implant</strong>s stimulate the cochlear<br />

nucleus (CN) and have the potential to<br />

provide NF2 patients hearing sensations that<br />

assist with sound awareness and<br />

communication.<br />

• implant housing<br />

containing implant circuitry<br />

and a powerful microchip<br />

• active electrode array<br />

placed on the cochlear nucleus<br />

during implantation


<strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong> Features<br />

• 12 contacts<br />

arranged on a soft, pre-shaped silicone paddle<br />

• Reliable, robust ceramic case,<br />

similar in hardness to the surrounding bone<br />

• MRI safe with no additional surgery necessary<br />

• Comprehensive telemetry<br />

• High-performance CIS+ speech coding<br />

with infinitely variable stimulation rates<br />

• Safety features<br />

output capacitors, telemetry, self-check integrity, etc.<br />

• Compatible with the TEMPO+ BTE<br />

speech processor including five wearing options<br />

3


4<br />

Special <strong>Implant</strong>s for Special Cases<br />

At MED-EL, we strive to continually offer the safest and most advanced implants<br />

for the treatment of severe hearing impairment. MED-EL offers a variety of<br />

cochlear implants, with options for special cases.<br />

<strong>COMBI</strong> <strong>40+</strong><br />

Standard <strong>El</strong>ectrode Array<br />

24 contacts arranged as connected pairs for<br />

12-channel high-rate stimulation. Deep<br />

electrode insertion for stimulation of the<br />

complete frequency range.<br />

<strong>COMBI</strong> <strong>40+</strong><br />

Compressed <strong>El</strong>ectrode Array<br />

(C<strong>40+</strong>S)<br />

For partial ossification or malformation of the<br />

cochlea.<br />

<strong>COMBI</strong> <strong>40+</strong><br />

Split <strong>El</strong>ectrode Array (C<strong>40+</strong> GB)<br />

For cases of complete cochlear ossification.<br />

Revolutionary technology: the <strong>COMBI</strong> <strong>40+</strong><br />

<strong>ABI</strong> (<strong>Auditory</strong> <strong>Brainstem</strong> <strong>Implant</strong>) provides<br />

Neurofibromatosis Type II patients hearing<br />

sensations for sound awareness and<br />

communication.<br />

Special Solutions<br />

MED-EL is committed to working<br />

with Cochlear <strong>Implant</strong> professionals<br />

to provide implant solutions for<br />

unique anatomical situations. Please<br />

contact your nearest MED-EL office<br />

for more information.


Benefits of the <strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />

Individuals vary in the amount of benefit they receive from the <strong>COMBI</strong> <strong>40+</strong><br />

<strong>ABI</strong>. While performance generally does not approach the levels common<br />

among recipients of cochlear implants,<br />

the <strong>ABI</strong> provides a variety of hearing sensations that are helpful for speech<br />

understanding and lip reading as well as environmental sound detection. For<br />

optimal performance, <strong>ABI</strong> candidates should understand the limitations of the<br />

implant and be committed to<br />

long-term rehabilitation and regular programming.<br />

<strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />

recipients report<br />

benefits in:<br />

• detecting everyday<br />

environmental sounds<br />

• face-to-face<br />

communication<br />

• greater confidence in<br />

social situations<br />

5


21060<br />

WORLDWIDE LEADER IN HEARING IMPLANTS<br />

MED-EL Worldwide Headquarters<br />

Fürstenweg 77a, A-6020 Innsbruck, Austria<br />

Tel.: +43-512-28 88 89<br />

Fax: +43-512-29 33 81<br />

office@medel.com<br />

MED-EL GmbH Niederlassung Wien<br />

office@at.medel.com<br />

MED-EL Deutschland GmbH<br />

office@medel.de<br />

MED-EL Deutschland GmbH Büro Berlin<br />

office-berlin@medel.de<br />

MED-EL Unità Locale Italiana<br />

ufficio.italia@medel.com<br />

VIBRANT MED-EL<br />

Hearing Technology France<br />

office@fr.medel.com<br />

MED-EL GmbH Sucursal España<br />

office@es.medel.com<br />

MED-EL GmbH Sucursal em Portugal<br />

office@pt.medel.com<br />

MED-EL UK Ltd<br />

office@uk.medel.com<br />

MED-EL Corporation<br />

(North America)<br />

implants@medelus.com<br />

MED-EL Latino America S.R.L.<br />

medel@medel.com.ar<br />

MED-EL Middle East FZE<br />

medeluae@emirates.net.ae<br />

MED-EL India Private Ltd<br />

implants@medel.in<br />

MED-EL China Office<br />

office@medel.net.cn<br />

MED-EL Singapore Regional<br />

Service Office<br />

office@sg.medel.com<br />

MED-EL Philippines<br />

Regional Headquarters<br />

office@ph.medel.com<br />

MED-EL Hong Kong Office<br />

office@hk.medel.com<br />

MED-EL Japan Co., Ltd<br />

info@medel.co.jp<br />

www.medel.com

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!